StudyFinder

A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults with Chronic Spontaneous Urticaria Inadequately Controlled bySecond Generation H1-Antihistamines

Status: Recruiting

The purpose of this study is to evaluate the efficacy of remibrutinib in comparison to dupilumab. We want to see which one works better for helping adults who have chronic spontaneous urticaria (CSU) and haven't had relief with use of second-generation antihistamines in treating adult participants who have CSU.

I'm interested

Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• diagnosis of Urticaria
Exclusion Criteria:

• prior use of remibrutinib, dupilumab or other BTK inhibitors
Interventions:

Drug: Dupilumab, Drug: Placebo solution for injection, Drug: Remibrutinib, Drug: Remibrutinib matching placebo

Conditions:

Dermatology (Skin, Hair & Nails)

Keywords:

Chronic Spontaneous Urticaria

Study Contact: Melissa Kelly - kell2061@umn.edu
Principal Investigator: Paul Bigliardi
Phase: PHASE3
IRB Number: STUDY00025930
See this study on ClinicalTrials.gov

Back